EX-FILING FEES 4 d268810dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

CALCULATION OF FILING FEE TABLE

Form S-8

(Form Type)

Alaunos Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1 - Newly Registered Securities

 

Security Type  

Security

Class

Title

 

Fee

Calculation

Rule

 

Amount

to be

Registered (1)

 

Proposed

Maximum

Offering

Price Per

Share

 

Proposed

Maximum

Aggregate

Offering

Price

 

Fee

Rate

 

Amount of

Registration

Fee

Equity

  Common Stock, par value
$0.001 per share, to be
issued under the
Registrant’s 2020 Equity
Incentive Plan
  Rules
457(c)
and
457(h)
  12,191,545(2)   $0.64(3)   $7,802,588.80   $92.70 per
$1,000,000
  $723.30

Equity

  Common Stock, par value
$0.001 per share, to be
issued under the
Registrant’s 2020 Equity
Incentive Plan
  Rule
457(h)
  3,058,455(4)   $1.48(5)   $4,526,513.40   92.70 per
$1,000,000
  $419.61

Total Offering Amounts

      $12,329,102.20       $1,142.91

Total Fee Offsets (6)

              $0

Net Fee Due

              $1,142.91

 

(1)

Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall be deemed to cover any additional shares of common stock that may become issuable under the ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan from time to time by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of the Registrant’s common stock.

 

(2)

Represents 12,191,545 shares reserved for future issuance under the Registrant’s 2020 Equity Incentive Plan.

 

(3)

Estimated in accordance with Rule 457(c) and (h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $0.64, which was the average of the high and low prices of the Registrant’s common stock as reported on The Nasdaq Global Select Market on March 25, 2022.

 

(4)

Represents shares of common stock underlying option awards granted and outstanding, but not registered, under the Registrant’s 2020 Equity Incentive Plan, as of March 29, 2022.

 

(5)

Estimated in accordance with Rule 457(h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $1.48, which is weighted-average exercise price for options outstanding, but not registered, under the 2020 Equity Incentive Plan, as of March 29, 2022.

 

(6)

The Registrant does not have any fee offsets.